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Abstract
Nicotine addiction begins with high-affinity binding of nicotine to acetylcholine (ACh) receptors 
in the brain. The end result is over 4,000,000 smoking-related deaths annually worldwide and the 
largest source of preventable mortality in developed countries. Stress reduction, pleasure, 
improved cognition, and other CNS effects are strongly associated with smoking. But, if nicotine 
activated ACh receptors found in muscle as potently as it does brain receptors, smoking would 
cause intolerable and perhaps fatal muscle contractions. Despite extensive pharmacological, 
functional, and structural studies of ACh receptors, the basis for the differential action of nicotine 
on brain vs. muscle ACh receptors has not been determined. Here we show that at the α4β2 brain 
receptors thought to underlie nicotine addiction, the high affinity of nicotine is the result of a 
strong cation-п interaction to a specific aromatic amino acid of the receptor, TrpB. In contrast, the 
low affinity of nicotine at the muscle-type receptor is largely due to the fact that this key 
interaction is absent, even though the immediate binding site residues, including the key TrpB, are 
identical in the brain and muscle receptors. At the same time a hydrogen bond from nicotine to the 
backbone carbonyl of TrpB is enhanced in the neuronal receptor relative to the muscle-type. A 
point mutation near TrpB that differentiates α4β2 and muscle-type receptors appears to influence 
the shape of the binding site, allowing nicotine to interact more strongly with TrpB in the neuronal 
receptor. ACh receptors are established therapeutic targets for Alzheimer’s disease, schizophrenia, 
Parkinson’s disease, smoking cessation, pain, attention deficit-hyperactivity disorder, epilepsy, 
autism, and depression1. Along with solving a chemical mystery in nicotine addiction, our results 
provide guidance for efforts to develop drugs that target specific types of nicotinic receptors.
Nicotinic acetylcholine receptors (nAChR) comprise a family of ≥ 20 homologous subtypes 
that mediate fast synaptic transmission throughout the central and peripheral nervous 
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systems2. The neuronal receptors are found in the central nervous system (CNS) and 
autonomic ganglia. Of these, the subtype most strongly associated with nicotine addiction 
and the target of recently developed smoking cessation drugs is termed α4β23–7. The high 
nicotine affinity of α4β2 receptors, when combined with the ability of nicotine to cross the 
blood-brain barrier and its favorable pharmacokinetics, allows nicotine at the submicromolar 
concentrations in tobacco smoke to acutely activate these receptors, providing reward, 
cognitive sensitization, and perhaps other effects. In addition, the high-affinity interaction 
allows smoked nicotine to act as an intracellular pharmacological chaperone of α4β2 
receptors, leading to the upregulation of receptors thought to underlie effects of chronic 
exposure6,8.
In previous studies of the nAChR of the neuromuscular junction (muscle-type), we showed 
that an important contributor to ACh binding is a cation-π interaction to a specific 
tryptophan (TrpB, residue 149, Fig. 1)9. These results were subsequently supported by the 
important series of crystal structures of ACh binding proteins (AChBP)10,11. These 
structures revealed the “aromatic box” structural motif of Fig. 1, and the aligning residues 
are predominantly aromatic throughout the Cys-loop family of neurotransmitter-gated ion 
channels. In other Cys-loop receptors, a cation-π interaction between the natural agonist and 
one of the aromatics is always seen, although its precise location varies12. Interestingly, 
when nicotine activates the muscle-type nAChR, there is no cation-π interaction13, 
consistent with its relatively low affinity for this receptor. This suggested that a cation-π 
interaction could discriminate between high affinity neuronal receptors and low affinity 
muscle-type receptors. However, subtle effects must be involved, as the nAChRs of the CNS 
and neuromuscular junction are homologous throughout most regions of sequence and are 
essentially identical in the immediate vicinity of the agonist binding site (Supplementary 
Fig. 1).
Here we describe studies of the α4β2 neuronal receptor. We find a remarkable alteration of 
binding behavior: both ACh and nicotine make a strong cation-π interaction to TrpB. In 
addition, a hydrogen bond from nicotine to the backbone carbonyl of TrpB that is weak in 
the muscle-type is much stronger in the α4β2 receptor. Taken together, these two 
noncovalent interactions fully rationalize the differential affinity of nicotine in the brain vs. 
the neuromuscular junction.
A cation-π interaction between a drug and a receptor can be revealed by incorporation of a 
series of fluorinated amino acid analogues (Fig. 2); a consistent trend in receptor response 
indicates a binding interaction. Such an experiment is enabled by the nonsense suppression 
methodology for incorporation of unnatural amino acids into receptors and channels 
expressed in Xenopus oocytes. While we have found the nonsense suppression methodology 
to be broadly applicable14,15, implementing the methodology for study of the α4β2 
neuronal nAChRs proved to be especially challenging, requiring new strategies. The α4β2 
receptors express in Xenopus oocytes at inadequately low levels for nonsense suppression 
experiments. However, recent studies showed that the Leu9’Ala (L9’A) mutation in the M2 
transmembrane helix of the α4 subunit greatly improves expression without altering the 
pharmacological selectivity of the receptor16. Therefore, all studies of α4β2 described here 
included this mutation. As with other mutations of L9’, the L9′A mutation lowers EC50 by 
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influencing receptor gating in ways that are fairly well understood and that do not distort the 
present analysis of the binding site (some 60Å from the 9’ position)17,18. In addition, 
previous studies of the muscle-type receptor used a comparable mutation at L9’, and control 
experiments established that it did not alter binding trends9,19.
The nAChRs are pentameric. The muscle-type receptor has a precise stoichiometry of 
(α1)2β1γδ. However, the α4β2 receptor can have variable stoichiometry. In particular, there 
are two forms of α4β2, (α4)2(β2)3 and (α4)3(β2)2, which we will refer to as A2B3 and 
A3B28,20,21. Agonist binding sites are at the appropriate α-β interfaces. The A2B3 form 
has higher sensitivity for nicotine and may be upregulated during chronic exposure to 
nicotine; our studies have focused on it. Controlling the ratios of mRNAs injected into the 
oocyte can reliably control subunit stoichiometry in the wild type receptor. However, in a 
nonsense suppression experiment, the subunit that contains the stop codon where the 
unnatural amino acid has been incorporated can exhibit low and variable expression levels. 
Therefore we sought a second, independent indicator of the stoichiometry of the α4β2 
receptor. We now report that the A2B3 and A3B2 forms of the α4(L9’A)β2 receptor show 
markedly different rectification behaviors. As indicated by either voltage ramp or voltage 
jump experiments, A2B3 is substantially more inward rectifying than A3B2 (Supplementary 
Fig. 2). Thus, in all our experiments with unnatural amino acids, the stoichiometries of 
mutant receptors are monitored by measuring I-V relations with voltage jumps. For each 
mutant receptor studied, we determined the fraction, (outward current at +70 mV/inward 
current at −110 mV), and a value ≤ 0.1 establishes the desired A2B3 stoichiometry 
(Supplementary Table 1, Supplementary Discussion). With these methodological 
developments in hand, incorporation of unnatural amino acids into the α4β2 receptor 
becomes feasible (Fig. 3).
As shown in Supplementary Table 1 and Fig. 4, a compelling “fluorination” trend is seen for 
both ACh and nicotine at TrpB of the α4β2 receptor. This is in sharp contrast to the results at 
the muscle-type receptor, in which no such trend is seen for nicotine activation. Further 
support for an important cation-π interaction for both agonists is provided by the large 
perturbation induced by a cyano (CN) group – which is strongly deactivating in a cation-π 
interaction – compared to a bromo (Br) group, which is roughly isosteric to CN but much 
less deactivating.
We have also evaluated other residues that constitute the aromatic box of the ACh binding 
site (Supplementary Table 1). The results for α4β2 very much parallel our previous findings 
for the muscle-type receptor (Supplementary Discussion). This indicates that it is 
specifically the interaction with TrpB that discriminates the two receptor subtypes.
The EC50 values reported here represent a measure of receptor function; shifts in EC50 can 
result from changes in ligand binding and/or receptor gating properties. By ascribing the 
results to attenuation of a cation-π interaction, we are effectively concluding that it is ligand 
binding that is being modulated by fluorination, but that conclusion is not incontrovertible. 
To resolve this ambiguity, we evaluated the gating behaviors of key receptors using single-
channel recording. For the wild type and the receptor with F3-Trp at TrpB, we compared the 
probabilities that the channel is open (Popen) at nicotine concentrations that evoke half-
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maximal macroscopic steady-state currents (EC50 = 0.08 µM and 1.2 µM, respectively). Any 
differences between the two Popen values must result from differences in gating behaviors. 
As suggested by Fig. 5 and as confirmed by further single-channel analysis (Supplementary 
Fig. 3 and Supplementary Discussion), the wild type and mutant receptors have Popen values 
that are essentially indistinguishable. Thus, the shift in EC50 for F3-Trp is primarily, if not 
exclusively, a consequence of changes in binding. Fluorination of TrpB of the α4β2 (A2B3) 
receptor primarily impacts sensitivity to nicotine by decreasing nicotine’s cation-π 
interaction with this residue.
These results indicate that nicotine is positioned more closely to TrpB in the α4β2 agonist 
binding site than in the muscle-type. This suggested that another nicotine binding interaction 
could also be altered. An important chemical distinction between ACh and nicotine is that 
only the latter can act as a hydrogen bond donor, through the pyrrolidine N+-H (Fig. 2A). 
Examination of the AChBP crystal structures (Fig. 1)22 suggested that the backbone 
carbonyl associated with TrpB could act as the hydrogen bond acceptor, and several groups 
have shown the importance of this interaction22–24. Previously, we probed this potential 
hydrogen bond in the muscle-type receptor by replacing the (i+1) residue with its α-hydroxy 
analogue (Fig. 2C). This converts the backbone amide to a backbone ester, which is well-
established to be a substantially poorer hydrogen bond acceptor. In the muscle-type receptor, 
this change raised the nicotine EC50 by a modest factor of 1.625. We now find that for 
precisely the same change in the α4β2 receptor, the nicotine EC50 increases 19-fold, a 
relatively large effect for such a subtle mutation26–28. Recall that the backbone ester 
substitution does not destroy the hydrogen bond, it simply attenuates it. Importantly, ACh, 
which cannot make a conventional hydrogen bond to the carbonyl, shows no shift in EC50 in 
response to this mutation (Supplementary Table 1). This establishes that the ester mutation 
does not globally alter the binding/gating characteristics of the receptor.
The differential affinity of nicotine for α4β2 vs. muscle-type receptors results from stronger 
interactions in the former with TrpB – both cation-π and hydrogen bonding. Since the two 
receptors are identical with regard to the five residues that make up the aromatic box, a 
factor “outside the box” must be influencing its precise geometry, such that nicotine can 
approach TrpB more closely in α4β2 than in muscle-type nAChR. In pioneering work, 
Grutter et al. sought residues responsible for the fact that α4β2 receptors show consistently 
higher affinity than the homopentameric α7 neuronal receptors29. At a particular residue in 
loop B – position 153, just four residues from TrpB – mutations strongly influence affinity. 
In high affinity α4β2 receptors this residue is a Lys, and this residue is proposed to help 
shape the aromatic box by forming a backbone hydrogen bond between loops B and C (Fig. 
1). In the lower affinity α7 neuronal receptor, residue 153 is a Gly, and molecular dynamics 
simulations of α7 suggest that a Gly at 153 discourages the formation of the hydrogen bond 
between loops B and C. Interestingly, the aligned residue in the muscle-type receptor is also 
Gly, and a naturally occurring G153S mutation is gain-of-function and associated with a 
congenital myasthenic syndrome30. We now report that the muscle-type α1 G153K mutant 
shows much higher affinity for nicotine, and that, when this mutation is present, the cation-π 
interaction to TrpB is strong. The data are summarized in Supplementary Table 1 and Figure 
4. As expected, the ACh cation-π interaction is maintained in the muscle-type receptor with 
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the G153K mutation. These data indicate that the loop B-loop C hydrogen bond that is 
naturally present in α4β2 shapes the aromatic box so that nicotine can make a closer contact 
to TrpB, and that this structural feature is absent or weaker in the muscle-type receptor.
Taken together, the present results indicate that the higher affinity of nicotine in the brain 
relative to the neuromuscular junction is a consequence of enhanced interactions with TrpB. 
A cation-π interaction that is absent in the muscle-type receptor is quite strong in α4β2. In 
addition, a hydrogen bond to a backbone carbonyl that is weak in the muscle-type is 
enhanced in α4β2. Both effects are quite substantial, and in combination they are more than 
adequate to fully account for the differential sensitivity to nicotine of the two receptors. The 
side chain of residue 153 in loop B distinguishes the two receptor types and apparently 
influences the shape of the binding site aromatic box, allowing a stronger interaction 
between nicotine and TrpB in high affinity receptors.
Methods Summary
Whole-cell electrophysiological characterization of agonist-induced responses
Rat α4β2 and mouse (α1)2β1γδ ion channels were expressed in Xenopus laevis oocytes. For 
α4β2 receptors, subunit stoichiometry was controlled by varying the α4:β2 subunit ratio and 
verified by voltage jump experiments. Dose-response measurements for these channels were 
performed with a holding potential of −60 mV.
Unnatural amino acid / α-hydroxy acid incorporation
Unnatural amino acids and α-hydroxy acids were prepared, coupled to dCA and ligated to 
74-mer THG73 as described previously15.
Single-channel characterization of α4β2
Single-channel recording was performed in the cell-attached configuration with a pipette 
potential of +100 mV as described previously27. Popen values were calculated from event-
detected data using Clampfit 9.2 single-channel search.
Full methods and any associated references are available in the online version of the paper at 
www.nature.com/nature.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
The binding site of AChBP, thought to resemble that of nAChRs. Shown are the four 
principal “loops” that define the binding site2. Also highlighted are TrpB (149) studied here; 
its backbone carbonyl (green star); and the α carbon on position 153, which has also been 
mutated here. Note that loop C contributes two aromatic residues; the other loops each 
contribute one. Image is of pdb file 1I9B10.
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Figure 2. 
Agonists and unnatural amino acids considered here. a. Structures of ACh and nicotine. b. 
Unnatural amino acids considered here. If not indicated, an a, b, c, or d group is H. c. The 
backbone ester strategy for modulating a hydrogen bond.
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Figure 3. 
Nonsense suppression in the α4β2 receptor. Shown is a wild type recovery experiment, in 
which Trp is incorporated at the TrpB position. a. Representative traces of voltage-clamp 
currents. Bars represent application of ACh at concentrations noted. b. Fit of data in A to the 
Hill equation.
Xiu et al. Page 10
Nature. Author manuscript; available in PMC 2009 October 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. 
Fluorination plots. Note that in both plots, all data sets share the point at x = 32.6 kcal/mol 
(cation-π energy for Trp); y = 0 (black circle). Moving to the left then corresponds to 
monofluoro-, difluoro-, trifluoro- and tetrafluoro-TrpB. Cation-π binding energies (x-axes) 
are from 9. a. Muscle-type receptor. The designation “wt" indicates G at position 153. b. 
α4β2 receptor.
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Figure 5. 
Single-channel recordings from wild type α4β2 (conventional expression) and the F3-Trp 
mutant (nonsense suppression) at site B, with nicotine applied at EC50 values (0.080 and 1.2 
µM, respectively). Lower traces are expansions of the regions marked by a bar in the upper 
trace. Records were obtained in the cell-attached configuration with a pipette potential of 
+100 mV and are shown at 2 kHz bandwidth. Channel openings are shown as downward 
deflections.
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